(1 - 30 von 34
)
Nivolumab und Cabozantinib: Zwei neue Wirkstoffe bei ...
www.aerzteblatt.de
Sep 28, · Cabozantinib konnte anders als Nivolumab das progressionsfreie Überleben von 3,8 auf 7,4 Monate verlängern, wie Toni Choueiri vom Dana-Farber Cancer Institute aus Boston und Mitarbeiter im …
Two new kidney cancer drugs 'work' - BBC News
www.bbc.com
Two new therapies for hard to treat advanced kidney cancer could change treatment of the disease, say experts at the European Cancer Congress.
Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death...
www.reuters.com
Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated...
Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of...
www.finanznachrichten.de
- Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of...
Grand Rounds - Toni Choueiri, MD - "Moving Forward in ...apps.winshipcancer.emory.edu › g...
apps.winshipcancer.emory.edu
Toni Choueiri, MD. Jerome and Nancy Kohlberg Chair and Professor of Medicine , Director, Lank Center for Genitourinary Oncology; Director, ...
Corona-Newsblog: Alle aktuellen Entwicklungen
www.schwaebische.de
Ihre Sterblichkeit sei doppelt so hoch „wie die durchschnittliche weltweite Sterblichkeit“, sagte der Onkologe und Co-Autor der Studie, Toni Choueiri, der Nachrichtenagentur AFP unter Verweis ...
Savolitinib: MET-Inhibitor bei fortgeschrittenem Nierenkrebs wirksam
www.aerzteblatt.de
Boston - Der experimentelle Tyrosinkinase-Hemmer Savolitinib, der die Signalweiterleitung des Onkogens c-Met hemmt, könnte erstmals eine zielgerichtete...
No clear link between statins and kidney cancer | Reuters
www.reuters.com
The cholesterol-lowering statin drugs are not linked to an increased risk of kidney cancer, suggests a new study. But there also isn't enough evidence to say...
Avastin raises heart failure risk in breast cancer
www.finanznachrichten.de
A team led by Dr. Toni Choueiri of Dana Farber Cancer Institute and Harvard Medical School in Boston analyzed data on advanced breast ...
Hometown Heroes | Dr. Toni Choueiri, Revs Season Member ...www.revolutionsoccer.net › post
www.revolutionsoccer.net
That's because Toni Choueiri is, in fact, Dr. Toni Choueiri, a senior physician and the Director of the Lank Center for Genitourinary Oncology at ...
Exelixis and Pfizer drugs compete in kidney cancer trial - Reuters
www.reuters.com
Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to...
Ipsen Announces Data Presentations of Cabozantinib (Cabometyx),...
www.finanznachrichten.de
Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Session: Presidential session 3 Oral presentation Monday, October
Reminder: Exelixis Announces Data Presentations, Webcast of Investor...
www.finanznachrichten.de
-- Oral Presentations for Medullary Thyroid Cancer, Castration-Resistant Prostate Cancer, Renal Cell Carcinoma and Hepatocellular Carcinoma -- Investor
European Cancer Congress 2015, Wien: Die Immunonkologie bleibt...
www.trillium.de
Toni Choueiri, Boston. Bei den ersten 375 Patienten wurde der primäre Endpunkt progressionsfreies Überleben, bei der Gesamtpopulation der sekundäre Endpunkt Gesamtüberleben analysiert. Der primäre Endpunkt wurde durch Cabozantinib von 3,8 auf 7,4 Monate nahezu verdoppelt (HR 0,58; p < 0,001), d. h. das Risiko für Progression oder Tod um ...
3 'targeted' cancer drugs raise risk of fatal side effects | (e)...
esciencenews.com
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new...
Certain Cancer Drugs May Have Fatal Side Effects: Analysis - Consumer...
consumer.healthday.com
Risk is very small, but doctors, patients should be made aware, investigators say
Biomarker test highly accurate in detecting early kidney cancer
www.newswise.com
A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early dete
Combination treatment improves outcomes in advanced kidney cancer...
www.azolifesciences.com
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared...
Coronavirus study: Cancer treatment not major COVID-19 risk ...www.usatoday.com › story › news › health ›
eu.usatoday.com
... may face, and to help guide treatment, said co-author Toni Choueiri, a genitourinary oncologist at the Dana-Farber Cancer Institute in Boston.
How kidney cancer affects the risks of coronavirus - Kidney ...www.kidneycancer.org › stories
www.kidneycancer.org
Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute/Brigham and Women's Hospital in Boston, ...
ASCO 2015: Tumoren des Urogenitalsystems - Trillium GmbH...
www.trillium.de
Diese Aktivität war beachtlich und dosisabhängig, so Toni Choueiri, Boston: In der Gruppe mit 0,3 mg/kg lag die mediane Überlebenszeit bei 16,4 Monaten, ...
Exelixis’ Partner Ipsen Announces European Commission Approval of...
apnews.com
These results were first presented by Dr. Toni Choueiri at the European Society for Medical Oncology (ESMO) Congress, and published ...
History of Changes for Study: NCT ClinicalTrials.govclinicaltrials.gov › history › NCT0...
clinicaltrials.gov
Principal Investigator: Toni Choueiri, MD. United States, South Carolina. Medical University of South Carolina [Recruiting] Charleston, South Carolina, United ...
Pazopanib Shows Better Quality-of-Life in Advanced Kidney Cancer
www.newswise.com
“Tolerability is a big part of the equation when drugs work equally well,” said Toni Choueiri, MD, director of the Kidney Cancer Center at ...
Mechanism for resistance to immunotherapy treatment discovered
medicalxpress.com
... led by Eliezer Van Allen, MD, of Dana-Farber and the Broad, and Toni Choueiri , MD, director of the Lank Center for Genitourinary Oncology ...
Gene mutation findings classify renal cell carcinoma
www.news-medical.net
Researchers have identified mutation-defined subtypes of clear cell renal cell carcinoma that have distinct clinical outcomes.
Cabozantinib extends PFS in metastatic renal cell carcinoma
www.healio.com
Toni K. Choueiri, MD. Toni Choueiri. “Cabozantinib is already approved in the second-line setting, and based on these data, I think there is real ...
Scientists report promising activity of novel targeted drug in ...www.news-medical.net › news › S...
www.news-medical.net
Toni Choueiri, MD, first author of the abstract. Choueiri is director of the Lank Center for Genitourinary Oncology and the Jerome and Nancy ...
sortiert nach Relevanz / Datum